Elyxyb (Celecoxib) Patent Expiration, LOE Window & CMS Spending

Elyxyb (Celecoxib) by Scilex: FDA Orange Book LOE 2036-05-27, 18 AB generics, $3.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorScilex
FDA Application & PathwayN212157 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-05-27
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$3.4M
2024 Medicare Part D Spend$1.7M
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel